Overview: Programming languages are the foundation of modern technologies, including artificial intelligence, cloud computing ...

Overview Data science jobs are growing fast in India. From AI engineers to data scientists, here is a list of top careers in ...

As automation replaces repetitive tasks and intelligent systems become more advanced, the demand for new types of skills is ...

Rock Springs Capital Management sold 202,918 shares of GPCR in the fourth quarter; the estimated transaction value was $8.29 million based on quarterly average pricing. Despite the sale, the ...

Feb 10 (Reuters) - Microsoft (MSFT.O), opens new tab is exploring using superconducting power lines in its data centers, which could potentially accelerate its massive U.S. build-out of the server ...

Federal immigration agents detain a man during an operation by Immigration and Customs Enforcement (ICE) and Border Patrol in St. Paul, Minnesota, on Jan. 27, 2026. (Photo by Octavio JONES / AFP via ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Abstract: This paper explores the potential of AI chatbots in enhancing the teaching of data structures and algorithms (DSA) in computer science education. We present our experience using AI chatbots ...

Geoff’s column hunts for how tech can make your life better — and advocates for you when tech lets you down. Got a question or topic to investigate? [email protected] and geoffreyfowler.88 ...

AI hardware needs to become more brain-like to meet the growing energy demands of real-world applications, according to researchers. In a study published in Frontiers in Science, scientists from ...

The last time I wrote an article on Structure Therapeutics Inc. (GPCR) it was in a Seeking Alpha article entitled "Structure Therapeutics: Potential To Have Best-In-class GLP-1 Agonist For Obesity ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...